Alopecia Areata Market Size in the 7MM was ~USD 180 Million in 2023, estimated DelveInsight

DelveInsight’s “Alopecia Areata Market Insights, Epidemiology, and Market Forecast – 2034” report delivers an in-depth understanding, historical and forecasted epidemiology, as well as the Alopecia Areata market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

The Alopecia Areata Market is an evolving segment of the global healthcare landscape, driven by the increasing Alopecia Areata prevalence of the disorder and the continuous development of innovative treatment options. The Alopecia Areata market encompasses various therapeutic categories, including antipsychotics, adjunctive therapies, and emerging treatment modalities.

Discover Key Insights into the Alopecia Areata Market with DelveInsight’s In-Depth Report @ Alopecia Areata Market Size

Key Takeaways from the Alopecia Areata Market Report

• In November 2024:- Applied Biology Inc.- The primary objective of the study is to assess the safety and efficacy of DA-001 as a treatment for telogen effluvium. DA-001 is a topical alpha 1 agonist combined with a TAAR receptor agonist. DA-001 was studies in a population of women that suffer from excessive shedding. DA-001 demonstrated significant reduction in hair shedding. This study aims to assess the safety and efficacy of DA-001 as a treatment for telogen effluvium).
• In November 2024:- Sanofi- A Phase 2, Randomized, Double-blind, Placebo–controlled, Parallel Group, 3-arm, Multinational, Multicenter, Proof-of-concept Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Adult Participants With Severe Alopecia Areata
• The market size in the 7MM is expected to grow exponentially at a CAGR of ~27% by 2034, owing to the increasing awareness and the launch of new therapies into the market during the forecast period (2024–2034).
• According to DelveInsight’s Epidemiology Model, total prevalent cases in the 7MM was approximately 1,500,000 in 2023; the cases are expected to increase due to genetic predisposition, rising autoimmune disorders, environmental triggers, modern lifestyles with high stress levels, poor dietary habits, and insufficient sleep.
• In 2023, the United States recorded the highest number of diagnosed prevalent cases, which were nearly 50% of the total diagnosed prevalent cases in the 7MM.
• Based on severity, Moderate cases accounted for the highest number of cases in the 7MM.
• Alopecia areata is associated with several complications, such as atopy, autoimmune disorders, psychological problems, nutritional deficiencies, and gastrointestinal diseases. In 2023, highest number of cases were observed for deficiencies, which were followed by atopy.
• The leading Alopecia Areata companies such as Arcutis Biotherapeutics, Bioniz Therapeutics, Reistone Biopharma Company, Pfizer, Suzhou Zelgen Biopharmaceuticals, Eli Lilly, Incyte Corporation, Aclaris Therapeutics, Legacy Healthcare, Concert Pharmaceuticals, LEO Pharma, Bristol-Myers Squibb, And Many Others
• Promising Alopecia Areata Therapies such as Abatacept, Tralokinumab, Secukinumab, BNZ 1, Ritlecitinib, Ifidancitinib, Coacillium topical, Delgocitinib, Etrasimod, Brepocitinib, ATI 1777, Baricitinib, and several others

Stay ahead in the Alopecia Areata Therapeutics Market with DelveInsight’s Strategic Report @ Alopecia Areata Market Outlook

Alopecia Areata Epidemiology Segmentation in the 7MM

• Alopecia Areata Prevalent Cases
• Alopecia Areata Diagnosed Cases
• Alopecia Areata Type-specific Cases
• Cases of Alopecia Areata Based on Age of Onset
• Alopecia Areata Severity-specific Cases
• Alopecia Areata Commorbidities associated
• Total Alopecia Areata Treated Cases

Download the report to understand which factors are driving Alopecia Areata epidemiology trends @ Alopecia Areata Prevalence

Alopecia Areata Marketed Therapies

• OLUMIANT (baricitinib): Eli Lilly and Company/Incyte Corporation

OLUMIANT is an oral, selective, reversible inhibitor of JAK1 and JAK2 that works inside the body by disrupting the cytokine signaling pathway involved in the Alopecia areata by inhibiting the activation of ATPase on JAK and blocks the signal transmission to cells through STATs. In June 2022, the US FDA approved OLUMIANT (baricitinib), a once-daily pill, as a first-in-disease systemic treatment for adults with severe alopecia areata.

• LITFULO (ritlecitinib): Pfizer

LITFULO is a kinase inhibitor which inhibits Janus kinase 3 (JAK3) and the tyrosine kinase expressed in hepatocellular carcinoma (TEC) family of kinases. In June 2023, the US FDA approved LITFULO (ritlecitinib), a once-daily oral treatment, for individuals 12 years of age and older with severe alopecia areata. Ritlecitinib has been shown to block the activity of signaling molecules and immune cells believed to contribute to loss of hair in people with alopecia areata. The FDA approval was based on results of ALLEGRO Phase IIb/III trial.

Alopecia Areata Emerging Therapies

• Etrasimod: Pfizer

Etrasimod is an oral, once-a-day, selective sphingosine 1-phosphate (S1P) receptor modulator developed by Pfizer. The company evaluates the drug for moderate-to-severe alopecia areata. In March 2022, Pfizer announced the acquisition of Arena Pharmaceuticals, a clinical-stage company developing innovative potential therapies for treating several immuno-inflammatory diseases. Currently, it is under Phase II development.

• Coacillium (LH-8): Legacy Healthcare

Coacillium (LH-8) is an investigational topical drug developed by Legacy Healthcare. Among the actives present in coacillium, various flavonoids, polyphenols and methylxanthines have been associated, enabling a pleiotropic mechanism to reverse immuno-inflammatory reactions and their deleterious consequences on hair follicles and adjacent dermal tissues. In a Phase II/III registration study ( RAAINBOW) in moderate and severe alopecia areata in children and adolescents, Coacillium cutaneous solution was superior to placebo after 24 weeks of treatment, both in terms of clinical efficacy and improvement of quality of life.

Get In-Depth Knowledge on Alopecia Areata Market Trends and Forecasts with DelveInsight @ Alopecia Areata Treatment Market

Alopecia Areata Market Outlook

Alopecia areata is a common autoimmune skin disease that causes hair loss on the scalp, face, and sometimes on other body areas. It affects people of all ages, both sexes, and all ethnic groups. It often appears during childhood and can be different for everyone. Therapy efficacy is difficult to estimate due to the unpredictable course of the disease, and spontaneous remission is often observed within the first year. The current therapies focus on immunosuppression that does not influence the long-term course of the disease, creating an unmet need for novel therapies.

Scope of the Alopecia Areata Market Report

• Coverage: 7MM
• Study Period: 2020-2034
• Alopecia Areata Companies: Arcutis Biotherapeutics, Bioniz Therapeutics, Pfizer, Eli Lilly and Company, Reistone Biopharma Company, Concert Pharmaceuticals, Suzhou Zelgen Biopharmaceuticals, Legacy Healthcare, Arena Pharmaceuticals, LEO Pharma, Aclaris Therapeutics, Bristol-Myers Squibb, Novartis, and many others.
• Alopecia Areata Drugs: Abatacept, Tralokinumab, Secukinumab, BNZ 1, Ritlecitinib, Ifidancitinib, Coacillium topical, Delgocitinib, Etrasimod, Brepocitinib, ATI 1777, Baricitinib, and several others.
• Alopecia Areata Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
• Alopecia Areata Unmet Needs, KOL’s views, Analyst’s views, Alopecia Areata Market Access and Reimbursement

Unlock Strategic Insights with DelveInsight’s Comprehensive Alopecia Areata Market Report @ Alopecia Areata Market Drivers and Barriers

Table of Content

1. Key Insights

2. Report Introduction

3. Alopecia areata Market Overview at a Glance

4. Executive Summary of Alopecia areata

5. Key Events

6. Disease Background and Overview

7. Alopecia areata Methodology

8. Alopecia areata Epidemiology and Patient Population

9. Alopecia areata Patient Journey

10. Marketed Alopecia areata Therapies

11. Emerging Alopecia areata Therapies

12. Alopecia areata: 7 Major Market Analysis

13. Alopecia areata SWOT Analysis

14. Alopecia areata Unmet Needs

15. Alopecia areata KOL Views

16. Alopecia areata Market Access and Reimbursement

17. Appendix

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/